** Casi Pharmaceuticals' shares fall 14.89% to $2.40 premarket
** Co says its application to start trials for its experimental antibody in patients with a type of complication related to kidney transplants was placed on clinical hold
** The complication, known as Antibody Mediated Rejection, occurs after a transplant when the recipient's immune system produces antibodies that attack the transplanted organ
** Co's application supporting early-to-mid stage trial of the antibody in adults with chronic immune thrombocytopenia, a rare autoimmune blood disorder, remains open
** Up to last close, stock down ~60% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.